Talus Bio

Talus Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.talus.bio

Last Round

Seed+

Aug 20, 2024

Est. Valuation

$19.7M

Total Funding Raised

$18.2M

Company Overview

Talus Bio is a biotechnology company that offers a data-enabled drug development platform for small-molecule therapies in oncology, integrating cell processing, high-sensitivity quantitative proteomics, and machine learning analytics to enhance drug discovery through gene regulation.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

transcription factor targetingsmall molecule drug discoveryundruggable targetsdrug discovery platformproteomics platformoncology drug discoveryprotein-protein interactionsPPI targetslive cell analysisbiopharma partnershipsnext-generation proteomicspreclinical therapeuticsgene regulationMARMOT platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Talus Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Talus Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Seed+Aug 20, 2024
SeedJun 6, 2022

Key People

Founding team and executive leadership

Lindsay Pino

Co-Founder And CTO

Founding Team

Alex Federation

Co-Founder, CEO

Founding Team

Talus Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2025

    Presented preclinical data on transcription factor therapeutic programs at AACR 2025.

  • Apr 25, 2025

    Presented at the AACR Annual Meeting 2025.

Talus Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Talus Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Talus Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range26
Year Founded2020
Last FundingAug 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.